Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas.

摘要: PURPOSETo assess the efficacy and toxicity of paclitaxel administered as a 96-hour infusion to patients with relapsed non-Hodgkin's lymphomas (NHLs).PATIENTS AND METHODSEligible had NHL measurable disease were considered incurable. Paclitaxel was infused at dose 140 mg/m2 every 3 weeks. Premedications prevent hypersensitivity reactions not no received corticosteroids. Expression multidrug resistance (mdr-1) gene determined in tumor from 17 by mRNA quantitative polymerase chain reaction (PCR).RESULTSThirty-one total 99 cycles paclitaxel. Two assessable for response. The median age 50 years, 71% stage IV disease, intermediate/high-grade histology present 65% patients. Patients three prior chemotherapy regimens, 68% responded previous (chemotherapy-sensitive). Of 29 patients...